Overview

Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2

Status:
Not yet recruiting

Trial end date:
2023-07-12

Target enrollment:

Participant gender:

Summary

A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of Mexiletine During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2 [The MIND Study]

Phase:

Phase 3

Details

Lead Sponsor:

Lupin Ltd.

Treatments:

Mexiletine